Last updated: February 14, 2026
What is the current market landscape for ND C: 42799-0952?
The drug associated with NDC 42799-0952 is Givosiran. It is marketed under the brand name Givlaari by Alnylam Pharmaceuticals. Givlaari is approved for the treatment of acute hepatic porphyria (AHP). The drug's market presence is limited to specialty biologic therapies for rare diseases.
How significant is the market for Givlaari?
Givlaari's sales data reflect its niche status. In 2022, estimated U.S. sales surpassed $100 million, with international expansion remaining nascent. The drug addresses a rare condition with an estimated prevalence of 1 in 50,000 individuals. Industry reports project growth driven by increased diagnosis and expanded indications.
Market drivers:
- Rare disease focus: Limited competition, high unmet need.
- Expanding indications: Research into broader porphyria treatments.
- Pricing: Approximate annual treatment cost exceeds $500,000 per patient.
Market constraints:
- Small patient population: Challenges scaling production profitably.
- Pricing pressure: Insurance restrictions and cost containment efforts.
What are current pricing and reimbursement policies?
Givlaari's list price ranges from $485,000 to $565,000 annually per patient, depending on dosing and administration. Payors typically require prior authorization, with coverage contingent on demonstrated diagnosis and treatment adherence.
Reimbursement tends to favor specialty pharmacies and hospital outpatient settings. Managed care organizations negotiate significant discounts, which can reduce net revenue by 20-40%.
What are projections for future prices?
Historical data suggests minimal price erosion for orphan biologics absent direct competition. Industry analysts predict:
- Price stability: Preserved due to the limited alternative treatments.
- Potential increases: Based on inflation adjustments and value-based pricing models.
However, emerging therapies, such as RNA interference (RNAi) or gene editing approaches, could challenge Givlaari's market dominance and drive down prices over the next 5-10 years.
How does the competitive landscape impact price projections?
-
Lack of direct competition: Currently, Givlaari has no approved rivals for AHP.
-
Pipeline candidates: Several investigational drugs aim to treat AHP, including:
- RNA-based therapies: Potential to offer similar efficacy at lower costs.
- Gene therapies: Advances could render existing treatments obsolete.
-
Regulatory incentives: Orphan drug designation extends exclusivity, delaying generic or biosimilar entry until 12 years post-approval in the U.S.
What are the key factors influencing future market prices?
| Factor |
Impact |
| Regulatory shifts |
Potential for extended exclusivity periods |
| Clinical trial outcomes |
Enhanced efficacy or safety could allow higher pricing, or conversely, reduced prices if new therapies are superior |
| Market penetration |
Broader use in related conditions increases revenue |
| Manufacturing advances |
Lower production costs could sustain higher profit margins |
| Pricing models |
Adoption of value-based pricing may restrict or enhance margins |
Summary of forecasts
- Short-term (1-3 years): Prices expected to remain stable, with slight increases aligned with inflation.
- Medium-term (4-7 years): Prices could face pressure if competition emerges or manufacturing efficiencies improve.
- Long-term (8-10 years): Likelihood that pricing declines because of new therapeutics and biosimilars, potentially reducing treatment costs by 20-50%.
Key takeaways
- Givlaari's market is constrained by the small pool of affected patients but has high per-patient pricing.
- Current reimbursement policies favor high prices, though managed care negotiations can reduce net revenues.
- Price stability is forecasted in the immediate term, with potential declines driven by competition and technological advancement.
- Limited competition extends exclusivity but also pressures from pipeline candidates could reshape the landscape over the next decade.
FAQs
Q1: What is the expected lifespan of Givlaari's market exclusivity?
A: Approximately 12 years post-approval in the U.S., assuming no patent challenges or regulatory changes.
Q2: Will biosimilars impact Givlaari prices soon?
A: Not in the immediate future, due to orphan drug exclusivity and complex biologic manufacturing.
Q3: How do international markets influence global price trends?
A: Countries with different healthcare systems may pay significantly lower prices, affecting global revenue projections.
Q4: Can emerging gene therapies replace Givlaari?
A: If clinical trials succeed, gene therapies could offer curative options, shifting the market away from current biologics.
Q5: What regulatory factors could influence pricing?
A: Policy changes promoting value-based pricing and extended exclusivity could support higher prices, whereas price control measures could reduce them.
Sources:
[1] Alnylam Pharmaceuticals, Givlaari product information.
[2] EvaluatePharma, Orphan drug market analysis, 2022.
[3] U.S. Food & Drug Administration (FDA), Orphan drug exclusivity policies.
[4] Medicare and private insurance formularies, 2022.
